Mario Rosario D.
- Country
- Italy
- Department
- UOSD Oncologia
Research Overview
- Phase II Randomized Trial of Atezolizumab Versus Atezolizumab Plus Bevacizumab in PD-L1 High Advanced Non-Small-Cell Lung Cancer
- Phase II Randomized Trial of Tedopi with Docetaxel or Nivolumab in Metastatic NSCLC Post-Chemoimmunotherapy
- Phase II Randomized Study on EGFR-TKI Sequencing with Dacomitinib and Osimertinib in Advanced EGFR-Mutant NSCLC
Data & Insights
Has run more than one trial at 21 of 62 partner sites.
Specializations
Lung Cancer Therapeutics
This investigator specializes in treating advanced non-small-cell lung cancer (NSCLC), with particular focus on developing innovative therapeutic approaches for metastatic disease stages.
- First-line Treatment Strategies
- Second-line Therapy Optimization
- Metastatic NSCLC Management
Their research encompasses both immunotherapy and targeted treatment approaches for lung cancer patients.
Precision Oncology
The investigator focuses on EGFR mutation-positive lung cancer treatment, exploring optimal therapeutic sequencing and targeted approaches for specific patient populations.
- EGFR-TKI Treatment Sequencing
- Brain Metastases Management
- Mutation-Specific Therapies
Their work includes evaluation of targeted therapies in patients with both classical and uncommon activating mutations.
Immunotherapy Research
The investigator studies immunotherapy combinations and their application in lung cancer treatment, including assessment of PD-L1 expression-guided therapeutic approaches.
- Chemoimmunotherapy Protocols
- Combination Treatment Strategies
- PD-L1 High Expression Therapeutics
Their research evaluates various immunotherapy combinations to optimize treatment outcomes in advanced NSCLC.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.